Deploying Bioavailability Enhancement Techniques to Improve Patients' Lives

Oral bioavailability is a constant challenge for developers of new chemical entities. Low solubility and permeability often reduce the fraction of an orally administered drug absorbed in the bloodstream. Increasing the dose to have adequate circulating drug at the intended site of action may not always be a feasible option. As such, drug developers need ways to improve the bioavailability of their molecules.

In this white paper, the experts at Piramal Pharma Solutions explain how their newly expanded Bioavailability Enhancement Platform is an enabling technology for the advancement of promising drug candidates into clinical development and beyond, making it a key part of PPS' focus on improving health outcomes for patients.